Detalles de la búsqueda
1.
Inherited alterations of TGF beta signaling components in Appalachian cervical cancers.
Cancer Causes Control;
30(10): 1087-1100, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31435875
2.
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Gynecol Oncol;
124(3): 575-81, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22112610
3.
Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.
Diagnostics (Basel);
12(4)2022 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35453890
4.
Ultrasonographic Visualization of the Ovaries to Detect Ovarian Cancer According to Age, Menopausal Status and Body Type.
Diagnostics (Basel);
12(1)2022 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35054294
5.
Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram.
Diagnostics (Basel);
12(1)2022 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35054310
6.
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Gynecol Oncol;
122(1): 121-6, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21496891
7.
Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma.
Int J Gynecol Cancer;
21(3): 494-9, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21430456
8.
MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer.
Diagnostics (Basel);
11(1)2021 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33419231
9.
Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance.
Biomedicines;
9(8)2021 Aug 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34440225
10.
Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers-Stage Challenges Categorical Assignments of Indolence & Aggressiveness.
Diagnostics (Basel);
10(2)2020 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31973035
11.
Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
Gynecol Oncol;
115(3): 389-95, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19800673
12.
Teaching gynecologic oncology in Low resource settings: a collaboration of health volunteers overseas and the society of gynecologic oncology.
Gynecol Oncol;
135(3): 580-2, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25308928
13.
Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery.
Healthcare (Basel);
7(3)2019 Jul 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31277282
14.
Expression and activity of taxane-metabolizing enzymes in ovarian tumors.
Gynecol Oncol;
108(2): 355-60, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18063021
15.
Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.
Anticancer Res;
28(3B): 1733-40, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18630452
16.
Percent surface area involvement is a predictor of lymph node metastasis in endometrial cancer.
Gynecol Oncol;
107(3): 482-6, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17850853
17.
Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
J Clin Oncol;
21(20): 3808-13, 2003 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14551299
18.
High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Cancer Genet Cytogenet;
159(2): 114-22, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15899382
19.
Clinicopathological effects of body composition measurements for patients with endometrial cancer.
Minerva Ginecol;
72(6): 430-435, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32720803
20.
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
Cancer;
116(23): 5407-14, 2010 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20737572